{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T15:05:30Z","timestamp":1774710330976,"version":"3.50.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","maturitas.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Maturitas"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1016\/j.maturitas.2014.04.016","type":"journal-article","created":{"date-parts":[[2014,5,2]],"date-time":"2014-05-02T01:00:15Z","timestamp":1398992415000},"page":"199-204","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"title":["Anti-sclerostin antibodies: Utility in treatment of osteoporosis"],"prefix":"10.1016","volume":"78","author":[{"given":"Bart L.","family":"Clarke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9773","key":"10.1016\/j.maturitas.2014.04.016_bib0005","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/S0140-6736(10)62349-5","article-title":"Osteoporosis: now and the future","volume":"377","author":"Rachner","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.maturitas.2014.04.016_bib0010","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/nrendo.2013.154","article-title":"Wnt signalling in osteoporosis: mechanisms and novel therapeutic approaches","volume":"9","author":"Canalis","year":"2013","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.maturitas.2014.04.016_bib0015","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/nrrheum.2011.130","article-title":"New targets for intervention in the treatment of postmenopausal osteoporosis","volume":"7","author":"Lewiecki","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.maturitas.2014.04.016_bib0020","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1517\/14712598.2014.895808","article-title":"Update on romosozumab: a humanized monoclonal antibody to sclerostin","volume":"14","author":"Costa","year":"2014","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.maturitas.2014.04.016_bib0025","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1210\/er.2011-1060","article-title":"Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases","volume":"33","author":"Ke","year":"2012","journal-title":"Endocr Rev"},{"key":"10.1016\/j.maturitas.2014.04.016_bib0030","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","author":"McClung","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.maturitas.2014.04.016_bib0035","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1056\/NEJMe1315500","article-title":"Sclerostin inhibition for osteoporosis \u2013 a new approach","volume":"370","author":"Becker","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.maturitas.2014.04.016_bib0040","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/jbmr.238","article-title":"Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis","volume":"26","author":"Cosman","year":"2011","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.maturitas.2014.04.016_bib0045","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0140-6736(13)60856-9","article-title":"Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial","volume":"382","author":"Tsai","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.maturitas.2014.04.016_bib0050","article-title":"Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: a randomized, double-blind, placebo-controlled study","author":"Padhi","year":"2013","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.maturitas.2014.04.016_bib0055","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/jbmr.173","article-title":"Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody","volume":"26","author":"Padhi","year":"2011","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.maturitas.2014.04.016_bib0060","doi-asserted-by":"crossref","first-page":"e62295","DOI":"10.1371\/journal.pone.0062295","article-title":"Anti-sclerostin antibody inhibits internalization of sclerostin and sclerostin-mediated antagonism of Wnt\/LRP6 signaling","volume":"8","author":"van Dinther","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.maturitas.2014.04.016_bib0065","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1359\/jbmr.081206","article-title":"Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis","volume":"24","author":"Li","year":"2009","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.maturitas.2014.04.016_bib0070","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1002\/jbmr.182","article-title":"Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats","volume":"25","author":"Li","year":"2010","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.maturitas.2014.04.016_bib0075","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1002\/jbmr.14","article-title":"Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength","volume":"25","author":"Ominsky","year":"2010","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.maturitas.2014.04.016_bib0080","doi-asserted-by":"crossref","DOI":"10.1002\/jbmr.2188","article-title":"Bone matrix quality following sclerostin antibody treatment","author":"Ross","year":"2014","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.maturitas.2014.04.016_bib0085","doi-asserted-by":"crossref","first-page":"628","DOI":"10.3109\/17453674.2011.625539","article-title":"Anti-sclerostin antibody and mechanical loading appear to influence metaphyseal bone independently in rats","volume":"82","author":"Agholme","year":"2011","journal-title":"Acta Orthop"},{"key":"10.1016\/j.maturitas.2014.04.016_bib0090","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/jor.22498","article-title":"Evaluation of the effects of systemic treatment with a sclerostin neutralizing antibody on bone repair in a rat femoral defect model","volume":"32","author":"Alaee","year":"2014","journal-title":"J Orthop Res"},{"key":"10.1016\/j.maturitas.2014.04.016_bib0095","doi-asserted-by":"crossref","first-page":"694","DOI":"10.2106\/JBJS.L.00285","article-title":"Systemic administration of sclerostin antibody enhances bone repair in a critical-sized femoral defect in a rat model","volume":"95","author":"Virk","year":"2013","journal-title":"J Bone Joint Surg Am"},{"key":"10.1016\/j.maturitas.2014.04.016_bib0100","first-page":"178","article-title":"Time-dependent effects of sclerostin antibody on a mouse fracture healing model","volume":"13","author":"Cui","year":"2013","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"10.1016\/j.maturitas.2014.04.016_bib0105","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1002\/jbmr.307","article-title":"Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones","volume":"26","author":"Ominsky","year":"2011","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.maturitas.2014.04.016_bib0110","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/jbmr.1803","article-title":"Sclerostin antibody treatment improves bone mass, bone strength, and bone defect regeneration in rats with type 2 diabetes mellitus","volume":"28","author":"Hamann","year":"2013","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.maturitas.2014.04.016_bib0115","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/jbmr.1717","article-title":"Sclerostin antibody improves skeletal parameters in a Brtl\/+ mouse model of osteogenesis imperfecta","volume":"28","author":"Sinder","year":"2013","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.maturitas.2014.04.016_bib0120","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1210\/en.2011-0252","article-title":"Increased bone formation and bone mass induced by sclerostin antibody is not affected by pretreatment or cotreatment with alendronate in osteopenic, ovariectomized rats","volume":"152","author":"Li","year":"2011","journal-title":"Endocrinology"},{"key":"10.1016\/j.maturitas.2014.04.016_bib0125","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/jbmr.2092","article-title":"Single- and multiple-dose randomized studies of blosozumab, a monoclonal antibody against sclerostin, in healthy postmenopausal women","volume":"29","author":"McColm","year":"2014","journal-title":"J Bone Miner Res"}],"container-title":["Maturitas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512214001352?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512214001352?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T08:59:50Z","timestamp":1759913990000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378512214001352"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["S0378512214001352"],"URL":"https:\/\/doi.org\/10.1016\/j.maturitas.2014.04.016","relation":{},"ISSN":["0378-5122"],"issn-type":[{"value":"0378-5122","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-sclerostin antibodies: Utility in treatment of osteoporosis","name":"articletitle","label":"Article Title"},{"value":"Maturitas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.maturitas.2014.04.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}